Endothelial dysfunctions: Common denominators in vascular disease

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 3, Issue 6, 2000, Pages 453-467

  De Caterina, Raffaele ^a,b,c  

^a SCUOLA SUPERIORE SANT ANNA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANTILIPEMIC AGENT; ANTIOXIDANT; CALCIUM ANTAGONIST; CAPTOPRIL; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN; ESTROGEN; IMMUNOGLOBULIN; INTEGRIN; MEVINOLIN; NITRIC OXIDE; PRAVASTATIN; PROSTAGLANDIN G2; PROSTAGLANDIN H2; SELECTIN; VITAMIN;

ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; ESTROGEN THERAPY; LEUKOCYTE ADHERENCE; REGULATORY MECHANISM; REVIEW; RISK FACTOR; VASCULAR ENDOTHELIUM; VASODILATATION;

ARTERIOSCLEROSIS; CELL ADHESION MOLECULES; ENDOTHELIUM, VASCULAR; HEMODYNAMIC PROCESSES; HUMANS; RISK FACTORS; VASCULAR DISEASES; VASODILATION;

EID: 0033638348     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075197-200011000-00007     Document Type: Review

References (117)

1. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine
2. Vascular endothelial dysfunction and the pathogenesis of atherosclerosis
3. Vascular endothelium in health disease
4. Leukocyte-endothelial interactions and the pathogenesis of atherosclerosis
5. Endothelial-leukocyte adhesion molecules in acute inflammation and atherogenesis
6. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis
7. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium
8. Cytokine signal transduction
9. Endothelial nuclear factor-κB and the initiation of the atherosclerotic lesion
10. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells
11. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers
12. Cytokines and growth factors in atherogenesis
13. Initiation of atherosclerotic lesions in cholesterol-fed rabbits. II. Selective retention of LDL vs. selective increases in LDL permeability in susceptible sites of arteries
14. Atherosclerosis: Basic mechanisms: Oxidation, inflammation, and genetics
15. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model
16. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes
17. Pulsatile flow and atherosclerosis in the human carotid bifurcation. Positive correlation between plaque location and low oscillating shear stress
18. Flow visualization in isolated transparent natural blood vessels
19. Carotid bifurcation atherosclerosis. Quantitative correlation of plaque localization with flow velocity profiles and wall shear stress
20. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree
21. Flow-mediated endothelial mechanotransduction
22. Hemodynamic forces are complex regulators of endothelial gene expression
23. Tyrosine phosphorylation of platelet endothelial cell adhesion molecule-1 (PECAM-1, CD31) in mechanically stimulated vascular endothelial cells
24. The distribution of fluid forces on model arterial endothelium using computational fluid dynamics
25. Subcellular distribution of shear stress at the surface of flow-aligned and nonaligned endothelial monolayers
26. Biology of the vessel wall
27. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: Cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxyde synthase are selectively up-regulated by steady laminar shear stress
28. Shear stress inhibits adhesion of cultured endothelial cells to lymphocytes by downregulating VCAM-1 expression
29. Laminar shear stress regulates VCAM-1 gene expression
30. Phosphorylation of endothelial nitric oxide synthase in response to fluid shear stress
31. Nitric oxide decreases cytokine-induced endothelial activation: Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines
32. Nitric oxide regulated vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells
33. Biomechanical activation: An emerging paradigm in endothelial adhesion biology
34. Soluble forms of vascular adhesion molecules, E-selectin, ICAM-1, and VCAM-1: Pathological significance
35. Soluble-phase adhesion molecules as biohumoral markers of vascular activation in vivo
36. Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atheroclerosis
37. Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin, and thrombomodulin
38. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men
39. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells
40. Atherosclerosis in Alaska Natives and non-natives
41. The effect of dietary ω-3 fatty acids on coronary atherosclerosis: A randomized, double-blind, placebo-controlled trial
42. The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of pro-atherogenic and pro-inflammatory proteins in human endothelial cells
43. Omega-3 fatty acids and endothelial leukocyte adhesion molecules
44. Control of endothelial leukocyte adhesion molecules by fatty acids
45. Nitric oxide decreases cytokine-induced endothelial activation: Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines
46. Nitric oxide attenuates vascular smooth muscle cell activation by interferon-gamma. The role of constitutive NF-kappa B activity
47. Effects of 17-beta-estradiol on cytokine-induced endothelial cell adhesion molecule expression
48. Selective estrogen receptor modulators: Different actions on vascular cell adhesion molecule-1 (VCAM-1) expression in human endothelial cells
49. Physiologic consequences of increased vascular oxidant stresses in hypercholesterolemia and atherosclerosis: Implications for impaired vasomotion
50. Superoxide production, risk factors, and endothelium-dependent relaxations in human internal mammary arteries
51. Biochemistry of nitric oxide and its redoxactivated forms
52. Oxidative modifications in nitrosative stress
53. Nitric oxide generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells
54. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin
55. Homocysteine, EDRF and endothelial function
56. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans
57. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions
58. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis
59. Effect of L-arginine on acetylcholine-induced endothelium-dependent vasodilation differs between the coronary and forearm vasculatures in humans
60. Endothelial function in health and disease: New insight into the genesis of cardiovascular disease
61. Endothelial function as an end-point in interventional trials: Concepts, methods and current data
62. The impact of coronary artery disease on coronary vasomotor response to non-ionic contrast media
63. The endothelium in coronary artery disease
64. A novel potent vasoconstrictor produced by vascular endothelial cells
65. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis
66. Plasma endothelin levels in humans with end stage heart failure and after cardiac transplantation
67. Contribution of endogenous degeneration of endothelin-1 to basal vascular tone
68. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans
69. Concentration of circulating plasma endothelin in patients with angina and normal coronary angiograms
70. New insight into coronary endothelial dysfunction: Role of endothelin
71. Eicosanoids and iso-eicosanoids: Constitutive, inducible and transcellular biosynthesis in vascular disease
72. 2 receptor antagonists inhibit endothelium-dependent contractions
73. Vasodilation to acetylcholine in primary and secondary forms of human hypertension
74. Angiotensin-converting enzyme. Vascular endothelial location
75. Conversion of angiotensin I to angiotensin II in dog isolated renal artery: Role of two different angiotensin II-generating enzymes
76. Short- and long-term determinants of cardiovascular function and therapy: Contributions of circulating and tissue renin-angiotensin systems
77. Angiotensin II receptors and functional correlates
78. Angiotensin-converting enzyme inhibitors
79. Safety and efficacy of angiotensin II receptor antagonists
80. Angiotensin II mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contributions to alterations of vasomotor tone
81. Angiotensin II stimulates NADH and NADPH activity in cultured vascular smooth muscle cells
82. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
83. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion
84. Vascular function in the forearm of hypercholesterolemic patients off and on lipid-lowering medication
85. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease
86. Effect of captopril and enalapril on endothelial function in hypertensive patients
87. Effect of lisinopril on endothelial function
88. Effect of antihypertensive drugs on endothelial function in humans
89. Effects of the calcium-antagonist mibefradil in epicardial and intramyocardial coronary arteries
90. Differential mobilization of calcium in endothelin-1-induced contractions in human arteries and veins: Effects of calcium antagonists
91. Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats
92. Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients
93. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT)
94. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease
95. Vitamin E consumption and the risk of coronary disease in women
96. Vitamin E consumption and the risk of coronary heart disease in men
97. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross cultural epidemiology
98. Risk of angina pectoris and plasma concentration of vitamins A, C, and E and beta carotene
99. Effect of vitamin E and beta carotene on the incidence of angina pectoris: A randomized, double-blind, controlled trial
100. Randomised controlled trial of vitamin E in patients with coronary disease. Cambridge Heart Antioxidant Study (CHAOS)
101. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction
102. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial
103. Effect of antioxidant vitamins on low density lipoprotein oxidation and impaired endothelium-dependent vasodilation in patients with hypercholesterolemia
104. Hormone therapy to prevent disease and prolong life in postmenopausal women
105. The Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial. Effects of estrogen or estrogen/progestin regimens in heart disease risk factors in postmenopausal women
106. No association of menopause and hormone replacement therapy with carotid intima-media thickness
107. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
108. Estrogen increases endothelial nitric oxide by a receptor-mediated system
109. Ethinyl estradiol acutely attenuates coronary vasomotor responses to acetylcholine in postmenopausal women
110. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women
111. Effects of estrogen replacement therapy on peripheral vasomotor function in postmenopausal women
112. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women
113. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease
114. 17-beta-estradiol therapy lessens angina in postmenopausal women with syndrome X
115. Regulation of P-selectin expression in human endothelial cells by nitric oxide
116. Reaction of nitric oxide with superoxide anion